1. Home
  2. LTGR vs NNNN Comparison

LTGR vs NNNN Comparison

Compare LTGR & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Long Table Growth Corp. Class A Ordinary Shares

LTGR

Long Table Growth Corp. Class A Ordinary Shares

N/A

Current Price

$9.96

Market Cap

229.1M

Sector

N/A

ML Signal

N/A

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$4.90

Market Cap

270.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTGR
NNNN
Founded
2025
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
229.1M
270.4M
IPO Year
2026
2023

Fundamental Metrics

Financial Performance
Metric
LTGR
NNNN
Price
$9.96
$4.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.6K
★ 199.7K
Earning Date
N/A
10-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$9.90
$4.66
52 Week High
$9.99
$44.73

Technical Indicators

Market Signals
Indicator
LTGR
NNNN
Relative Strength Index (RSI) 54.60 28.21
Support Level $9.91 N/A
Resistance Level $9.99 $6.95
Average True Range (ATR) 0.01 0.55
MACD 0.00 0.05
Stochastic Oscillator 62.50 7.01

Price Performance

Historical Comparison
LTGR
NNNN

About LTGR Long Table Growth Corp. Class A Ordinary Shares

Long Table Growth Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: